Bispecific Therapy
Bispecific T-cell Engager Therapy
Bispecific antibody drugs are among the growing number of immunotherapies offering promising new options for treating certain types of cancer that are often resistant to treatment. These drugs boost the action of the body’s immune system to find, target, and kill cancer cells effectively.
Bispecific antibodies are engineered to bind to both cancer cells and healthy immune cells (T-cells) at the same time. This connection activates the T-cells to recognize and destroy the cancerous cells.
Bispecific therapy is initially administered on a step-up dosing schedule to help minimize adverse effects. There is a risk of unique side effects, including cytokine release syndrome (CRS) and neurotoxicities, which can be life-threatening. Initial treatments are typically administered in an inpatient hospital setting to monitor for any serious adverse reactions. Patients can then proceed with ongoing maintenance on an outpatient basis.
For adults with relapsed or refractory multiple myeloma:
- Elranatamab (ELREXFIO™)
- Linvoseltamab (LYNOZYFIC™)
- Talquetamab (TALVEY™)
- Teclistamab (TECVAYLI®)
For adults with relapsed or refractory large B-cell lymphomas, including diffuse large B-cell lymphoma:
- Glofitamab (COLUMVI™)
- Epcoritamab (EPKINLY™)
For adults with relapsed or refractory follicular lymphoma:
- Mosunetuzumab (LUNSUMIO™)
- Epcoritamab (EPKINLY™)
For adults with extensive-stage small cell lung cancer with disease progression on or after platinum-based chemotherapy:
- Tarlatamab (IMDELLTRA™)
Advanced Bispecific T-cell Therapy Program Available in an Outpatient Setting
FCS provides bispecific step-up dosing in select locations in collaboration with local hospitals. This ensures that hospital observation is available when needed.
Stabilized patients also have the opportunity to proceed with ongoing maintenance on an outpatient basis in a convenient and comfortable setting. Skilled FCS clinical professionals provide personalized one-to-one monitoring, oversight, and treatment guidance to reduce symptoms and slow the progression of the disease to remission.
FCS offers step-up dosing and maintenance therapy with FDA-approved bispecific drugs, all proven effective in treating specific cancers.
Bispecific Therapy Educational Videos
Learn how bispecific antibody therapy is changing the way some cancers are treated. Ameet Patel, MD, Director of Cell Therapy, and Sarah Rockwell, PharmD, BCOP, Clinical Oncology Pharmacist, explain how this innovative immunotherapy works by bringing T-cells and cancer cells together to help the immune system find and attack cancer. Watch either video below — one covers what patients can expect during step-up dosing treatment, including possible side effects to watch for, and the other explores how FCS’s bispecific maintenance program continues to bring cutting-edge cancer care to patients close to home.
Anthony’s Story
Life-Changing Treatment Close to Home
At Florida Cancer Specialists & Research Institute (FCS), patients like Anthony are seeing life-changing results through access to cutting-edge treatments close to home. After being diagnosed with a rare, aggressive lung cancer, Anthony began therapy with Talatamab at our Brooksville location, eliminating the need to travel out of state. With expert care from the FCS team, his health and quality of life quickly improved. This is the impact of personalized, innovative cancer care at FCS.